177Lu-Dotatate efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase 2 prospective clinical trials

#3305

Introduction: Neuroendocrine tumors are a rare neoplasia. At least 25% of patients (pts) with advanced disease may have functioning neuroendocrine tumors (F-NETs) that can secrete bioactive peptides that can lead to specific symptoms like diarrhea that can be debilitating and life-threatening.Although symptom relief is available with somatostatin analogs (SSA), the disease eventually becomes refractory to SSA,leaving no proven treatment options

Aim(s): Our aim was to assess the efficacy of 177Lu-DOTATATE in metastatic F-NETs pts in progression from previous treatments and refractory to SSA

Materials and methods: We conducted a not pre-planned joint analysis on metastatic F-NET pts enrolled into 2 phase 2 studies and treated with 18.5 or 27.5 GBq of 177LU-DOTATATE. Syndrome Response(SR),Overall Survival(OS),Progression-Free Survival(PFS),tolerance,Objective Response Rate(ORR) and disease control rate(DCR) were analysed

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M,

Keywords: neuroendocrine tumor, carcinoid syndrome, neuroendocrine neoplasia, PRRT, insulinoma, 177Lu-Dotatate, functioning tumor,